

1  
2  
3  
4  
5 UNITED STATES DISTRICT COURT  
6 WESTERN DISTRICT OF WASHINGTON  
7 AT TACOMA

8 UNITED STATES OF AMERICA,

CASE NO. CR20-5270 BHS

9 Plaintiff,

ORDER

v.

10 RICHARD MARSCHALL,

11 Defendant.

12  
13 This matter comes before the Court on limited remand from the Ninth Circuit to  
14 enable the Court “to state, orally or in writing, the reasons for its order denying  
15 appellant’s motion for bail pending appeal.” Order, *United States v. Marschall*, No. 22-  
16 30048 (9th Cir. Apr. 18, 2022) (quoting Fed. R. App. P. 9(b); and citing 18 U.S.C.  
17 § 3143(b); *United States v. Wheeler*, 795 F.2d 839, 841 (9th Cir. 1986)); *see also* Dkt.  
18 298.

19 Under 18 U.S.C. § 3143(b),

20 [A] judicial officer shall order that a person who has been found guilty of  
21 an offense and is sentenced to a term of imprisonment, and who has filed an  
22 appeal . . . be detained, unless the judicial officer finds—

1 (A) by clear and convincing evidence that the person is not likely to flee or  
 2 pose a danger to the safety of any other person or the community if  
 released . . . ; and

3 (B) that the appeal is not for the purpose of delay and raises a substantial  
 question of law or fact likely to result in—

4 (i) reversal,

(ii) an order for a new trial,

5 (iii) a sentence that does not include a term of imprisonment, or

6 (iv) a reduced sentence to a term of imprisonment less than the total  
 of the time already served plus the expected duration of the appeal  
 process.

7 18 U.S.C. § 3143(b)(1).

8 A question is substantial if it is “of more substance than would be necessary to a finding  
 9 that it was not frivolous.” *United States v. Garcia*, 340 F.3d 1013, 1020 n.5 (9th Cir.  
 10 2003) (internal quotations omitted). The defendant has the burden to prove he is entitled  
 11 to bail pending appeal. *United States v. Handy*, 761 F.2d 1279, 1283 (9th Cir. 1985).

12 While there is no suggestion that Marschall poses a flight risk, the Court cannot  
 13 confidently say that he would not pose a danger to the safety of any other person or the  
 14 community if he were released. This is Marschall’s third conviction under the same  
 15 statute, and while it is a nonviolent crime, it is a serious one.<sup>1</sup> In terms of his most recent  
 16 conviction, Marschall sold a purported cure for serious ailments such as MRSA and  
 17 COVID-19 in the midst of the COVID-19 pandemic.

---

18  
 19  
 20 <sup>1</sup> The Government presented evidence in its sentencing memorandum that Marschall  
 21 continued to prescribe drugs and use the designation N.D. during and even after his trial in this  
 22 case, despite his convictions and the revocation of his naturopathic license. Dkt. 279 at 11; Dkt.  
 281. While the Court did not take this evidence into consideration at sentencing, it is directly  
 relevant to the determination whether Marschall has met his burden to show by clear and  
 convincing evidence that he does not pose a danger to the community.

1       The Court recognizes, however, that given Marschall’s relatively brief sentence,  
2 he will soon be released and may pose a danger to the community. Nevertheless, the  
3 Court does not believe that Marschall can raise a substantial question likely to result in a  
4 reversal, a new trial, a sentence not including a term of imprisonment, or a sentence less  
5 than time served plus the expected duration of the appeal. Marschall was sentenced at the  
6 low end of the guideline range, and his arguments regarding the constitutionality of the  
7 underlying statute, the legitimacy of his prosecution, and the jury instructions have all  
8 been addressed, most of them more than once, by two different judges.<sup>2</sup>

9       Marschall has repeatedly argued that the indictment is faulty because it failed to  
10 allege a *mens rea* element. *See* Dkt. 76 (Motion to Dismiss); Dkt. 206 (Motion for  
11 Miscellaneous Relief). He now again seeks to advance that argument, claiming that his  
12 prosecution violated the Supreme Court’s holding in *Rehaif v. United States*, 139 S. Ct.  
13 2191 (2019), and the Ninth Circuit’s holdings in *United States v. Watkins*, 278 F.3d 961  
14 (9th Cir. 2002), and *United States v. Kaplan*, 836 F.3d 1199 (9th Cir. 2016), because it  
15 did not contain a *mens rea* element. Dkt. 298 at 13.

16       Marschall was indicted, prosecuted, and convicted under 21 U.S.C. § 331(a) which  
17 prohibits “[t]he introduction or delivery for introduction into interstate commerce of  
18 any . . . drug . . . that is adulterated or misbranded.” That crime is converted to a felony  
19 and carries a maximum term of imprisonment of three years if the person “commits such  
20 a violation after a conviction of him under this section has become final, or commits such

---

21  
22       <sup>2</sup> This case was previously assigned to the Honorable Robert J. Bryan. The case was  
reassigned to the undersigned after the first trial ended in a mistrial. *See* Dkts. 185, 192.

1 a violation with the intent to defraud or mislead . . . .” *Id.* at § 333(a)(2). In Marschall’s  
 2 two prior convictions, the Government charged him with misbranding drugs with the  
 3 intent to defraud or mislead. Dkt. 298 at 3. In the instant case, the Government charged  
 4 Marschall with misbranding drugs after being previously convicted of misbranding drugs.  
 5 *See* Dkt. 38 at 5.

6 In *Rehaif*, the Supreme Court examined a conviction for unlawful possession of a  
 7 firearm. The crime in that case, like the misbranding crime, is split between a “prohibited  
 8 act” statute and a “penalty provision” statute. The penalty provision contained a  
 9 “knowingly” *mens rea* element, which provides that if a person knowingly violates 18  
 10 U.S.C. § 922(g), that person can be fined or imprisoned for a maximum of 10 years, or  
 11 both. 18 U.S.C. § 924(a)(2). A violation of § 922(g) required both that the person have a  
 12 certain status, such as being “illegally or unlawfully in the United States,” *and* that the  
 13 person transport a firearm or ammunition in interstate commerce. 18 U.S.C. § 922(g).  
 14 The Supreme Court held that the “knowingly” *mens rea* element in the penalty provision  
 15 applied to both requirements of § 922(g), i.e., the defendant had to know both that he was  
 16 illegally in the United States and that he transported a firearm in interstate commerce. *See*  
 17 *Rehaif*, 139 S. Ct. at 2198–99. The focus in that case was on Congress’ intent and the  
 18 presumption of scienter in the absence of clear Congressional intent. *See id.* at 2195.

19 The misbranding statutory scheme is notably different. While it also has both a  
 20 prohibited act statute and a penalty provision statute, the penalty provision statute  
 21 provides two ways in which an act of misbranding can be converted into a felony:  
 22 (1) “after a conviction of [the defendant] under [§ 331] has become final,” or (2) when

1 the defendant commits the crime “with the intent to defraud or mislead.” 21 U.S.C.  
2 § 333(a)(2). Here, unlike in *Rehaif*, Congress clearly intended to allow for a felony  
3 conviction without proof of *mens rea* when the defendant has previously been convicted  
4 of misbranding drugs. Marschall also misinterprets *Watkins* and *Kaplan*. In both cases,  
5 the Ninth Circuit examines only the “intent to defraud or mislead” charging option in  
6 § 333(a)(2), and they are therefore inapplicable to the facts of this case.

7 The statute does not require the Government to prove *mens rea*, and it was  
8 therefore proper for the Government not to include a *mens rea* element in the indictment  
9 and for the Court not to instruct the jury on *mens rea*. This argument does not raise a  
10 substantial question for appeal.

11 Marschall has also repeatedly argued that the substances he sold are not “drugs”  
12 but are dietary supplements—a claim that the jury had to disagree with to reach a guilty  
13 verdict. *See* Dkt. 45 (Motion to Dismiss); Dkt. 99 (Motion in Limine); Dkt. 206 (Motion  
14 for Miscellaneous Relief). Whether a substance is a drug under the statute depends on its  
15 intended use. While the same product could be considered a food or a dietary supplement  
16 in other contexts, that classification depends on their intended use. The jury in this case  
17 found that Marschall intended to use the substances as drugs—“for use in the diagnosis,  
18 cure, mitigation, treatment, or prevention of disease . . . .” 21 U.S.C. § 321(g)(1). Such a  
19 finding was supported by the evidence presented at trial.

20 Post-trial, Marschall challenged the Court’s refusal to provide to the jury the full  
21 statutory definition of “drug” or the definitions of “health claim” and “structure/function  
22 claim.” Dkt. 271 at 9–13. He also argued that he was entitled to a judgment of acquittal

1 because the Government relied solely on his uncorroborated confession to convict him.  
2 *Id.* at 13–15. The Court again fully considered those arguments and denied them. Dkt.  
3 275 at 3–5.

4 A review of 21 U.S.C. §§ 321 and 343 clearly shows how confusing and  
5 misleading the proposed statutory definitions would be to a jury. The entire statutory  
6 definition of “drug” alone refers to four different ways a substance can be considered a  
7 drug, a few ways a food or dietary supplement would not be considered a drug, and three  
8 other statutory provisions which themselves cite to other statutory provisions and  
9 regulations. *See* 21 U.S.C. § 321(g)(1). Further, the types of claims referred to in the  
10 statute that would render a food or dietary supplement not a drug are claims either  
11 required or approved by the Secretary of Health and Human Services. *See generally* 21  
12 U.S.C. §§ 343(q)–(r). That clearly and facially does not apply to this case where  
13 Marschall was convicted for misbranding drugs that he claimed could “*crush* 30 different  
14 viral infections, including those in the Corona family like in China, 40 different bacterial  
15 infections, 25 different fungal infections and 20 different parasitic infections like  
16 amoeba.” Dkt. 210 at 3 (emphasis in original). He also made claims that one of the  
17 products, Allicin, does not just “boost the immune system, *it just kills the virus.*” *Id.* at 4  
18 (emphasis in original). These are objectively not claims required or approved by the  
19 Secretary of Health and Human Services.

20 Marschall’s proposed jury instructions, including those for the complete statutory  
21 definitions of “drug,” “structure/function claims,” and “health claims,” would have  
22

1 served to confuse and mislead the jury and were irrelevant. They were properly excluded,  
2 and that exclusion does not raise a substantial question for appeal.

3        Marschall argues that he was not provided any notice that he was making “disease  
4 claims.” Dkt. 298 at 18–20. Such notice is not required. Marschall violated a criminal  
5 statute, and the Government enjoys prosecutorial discretion. While the Food and Drug  
6 Administration has discretion to warn or notify individuals or entities it believes are  
7 violating FDA regulations, the Government is not required to provide an individual  
8 notice or an opportunity to cease his unlawful activity before charging him. Marschall  
9 was afforded due process and had the opportunity to be heard during both of his trials,  
10 and his argument that the Government failed to notify him prior to indicting him does not  
11 raise a substantial question for appeal.

12        Marschall has again repeatedly argued that the underlying statute violates the First  
13 Amendment both on its face and as applied to him. *See* Dkt. 44 (Motion to Dismiss); Dkt.  
14 100 (Motion in Limine); Dkt. 206 (Motion for Miscellaneous Relief). Marschall argued  
15 that the statute at issue unconstitutionally regulates speech because the intended use of  
16 the substance makes it a drug. But the statute regulates conduct in that it forbids the sale  
17 of misbranded drugs in interstate commerce. *See* Dkt. 87 at 3. While it is true that  
18 whether a substance is a drug depends on its intended use, to be prosecuted under the  
19 statute, the individual still must engage in the conduct of misbranding the drug and  
20 selling it in interstate commerce.

21        Marschall argues that his claims about the “Dynamic Duo” were not false or  
22 misleading and were substantiated at trial. But Marschall’s own sentencing memorandum

1 proves that is not true. He himself stated that “[n]o one actually believed that garlic and  
2 larch starch could cure COVID-19, not even Mr. Marschall.” Dkt. 282 at 5. That  
3 statement directly contradicts his previous claims that the Dynamic Duo could “crush”  
4 COVID-19, along with other serious illnesses.

5 He also argues that the prosecution did not advance a substantial government  
6 interest. Dkt. 298 at 22. The Court again reiterates that Marschall’s conduct is serious and  
7 not as banal as he suggests. Marschall advertised and sold unauthenticated and  
8 unauthorized “cures” for COVID-19 in the midst of a pandemic. While it is possible that  
9 the Dynamic Duo may never have directly caused anyone serious health problems,  
10 encouraging alternative and unproven treatments for a serious virus that was spreading  
11 globally could encourage people to forgo life-saving treatment that could protect them  
12 from the effects of the virus and protect others from the spread of the virus.

13 It is for all of the above stated reasons why the Court denied Marschall bail  
14 pending appeal.

15 **IT IS SO ORDERED.**

16 Dated this 20th day of April, 2022.

17  
18 

19 BENJAMIN H. SETTLE  
20 United States District Judge  
21  
22